Capstone Investment Advisors
ATOS icon

Capstone Investment Advisors’s Atossa Therapeutics ATOS Stock Holding History

Capstone Investment Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,417
Closed -$108K – 1714
2021
Q1 		$108K Buy
+3,417
New +$125K ﹤0.01% 1511

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capstone Investment Advisors's ATOS Position: Q2 2021 in Review

Capstone Investment Advisors sold out of Atossa Therapeutics (ATOS) in Q2 2021, closing a stake of 3,417 shares — an estimated $108K sold.

Capstone Investment Advisors first reported a position in ATOS in Q1 2021 and held it in 1 quarter. The position peaked at $108K in Q1 2021. 86 funds tracked by Wall St. Rank hold ATOS as of Q2 2021.

  • Capstone Investment Advisors reported no remaining Atossa Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 3,417 Atossa Therapeutics shares in Q2 2021, an estimated $108K.
  • Capstone Investment Advisors first reported a position in Atossa Therapeutics in Q1 2021 and held it in 1 quarter.
  • Capstone Investment Advisors's Atossa Therapeutics position peaked at $108K in Q1 2021.
  • 86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2021.

Based on Capstone Investment Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.